Literature DB >> 10451460

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

M J Alter1, D Kruszon-Moran, O V Nainan, G M McQuillan, F Gao, L A Moyer, R A Kaslow, H S Margolis.   

Abstract

BACKGROUND: Because many persons with chronic hepatitis C virus (HCV) infection are asymptomatic, population-based serologic studies are needed to estimate the prevalence of the infection and to develop and evaluate prevention efforts.
METHODS: We performed tests for antibody to HCV (anti-HCV) on serum samples from 21,241 persons six years old or older who participated in the third National Health and Nutrition Examination Survey, conducted during 1988 through 1994. We determined the prevalence of HCV RNA by means of nucleic acid amplification and the genotype by means of sequencing.
RESULTS: The overall prevalence of anti-HCV was 1.8 percent, corresponding to an estimated 3.9 million persons nationwide (95 percent confidence interval, 3.1 million to 4.8 million) with HCV infection. Sixty-five percent of the persons with HCV infection were 30 to 49 years old. Seventy-four percent were positive for HCV RNA, indicating that an estimated 2.7 million persons in the United States (95 percent confidence interval, 2.4 million to 3.0 million) were chronically infected, of whom 73.7 percent were infected with genotype 1 (56.7 percent with genotype 1a, and 17.0 percent with genotype 1b). Among subjects 17 to 59 years of age, the strongest factors independently associated with HCV infection were illegal drug use and high-risk sexual behavior. Other factors independently associated with infection included poverty, having had 12 or fewer years of education, and having been divorced or separated. Neither sex nor racial-ethnic group was independently associated with HCV infection.
CONCLUSIONS: In the United States, about 2.7 million persons are chronically infected with HCV. People who use illegal drugs or engage in high-risk sexual behavior account for most persons with HCV infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10451460     DOI: 10.1056/NEJM199908193410802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  609 in total

Review 1.  Hepatitis C in pregnancy.

Authors:  N Hadzić
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

2.  Lack of awareness of hepatitis C risk among persons who received blood transfusions before 1990.

Authors:  J Buffington; R Rowel; J M Hinman; K Sharp; S Choi
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  The science, economics, and effectiveness of combination therapy for hepatitis C.

Authors:  G Dusheiko; E Barnes; G Webster; S Whalley
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

4.  Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection.

Authors:  S Anderson; C L Nevins; L K Green; H El-Zimaity; B S Anand
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

5.  Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance.

Authors:  Matthias Schröter; Bernhard Zöllner; Peter Schäfer; Andreas Reimer; Matthias Müller; Rainer Laufs; Heinz-Hubert Feucht
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

6.  The impact of hepatitis C in general practice.

Authors:  S Singh; R Miller; S Madge; D Patch
Journal:  Br J Gen Pract       Date:  2000-07       Impact factor: 5.386

7.  Refugees, asylum seekers, and general practice: room for improvement?

Authors:  S Hargreaves; A Holmes; J S Friedland
Journal:  Br J Gen Pract       Date:  2000-07       Impact factor: 5.386

8.  Influence of Injection Drug Use-Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen Among Virally Suppressed Individuals.

Authors:  Keri L Calkins; Catherine R Lesko; Geetanjali Chander; Richard D Moore; Bryan Lau
Journal:  J Acquir Immune Defic Syndr       Date:  2018-03-01       Impact factor: 3.731

Review 9.  Modulation of immune responses following solid organ transplantation by microRNA.

Authors:  Nayan J Sarma; Venkataswarup Tiriveedhi; Sabarinathan Ramachandran; Jeffrey Crippin; William Chapman; T Mohanakumar
Journal:  Exp Mol Pathol       Date:  2012-10-01       Impact factor: 3.362

10.  Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans.

Authors:  Jeffrey P Anderson; Eric J Tchetgen Tchetgen; Vincent Lo Re; Janet P Tate; Paige L Williams; George R Seage; C Robert Horsburgh; Joseph K Lim; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Marina B Klein; Amy C Justice
Journal:  Clin Infect Dis       Date:  2013-11-27       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.